SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 9.99% Stake in Silo Pharma, Inc.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a 9.99% beneficial ownership stake in Silo Pharma, Inc. through a Schedule 13G filing, stemming from a recent Securities Purchase Agreement.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership of Silo Pharma, Inc. common stock.
• As of May 21, 2025, the Reporting Persons collectively beneficially own 784,630 shares of Silo Pharma, Inc. common stock, representing 9.99% of the class.
• This ownership includes 481,600 shares directly held by Intracoastal and 303,030 shares issuable upon the exercise of Intracoastal Warrant 2.
• The beneficial ownership percentage is capped at 9.99% due to "blocker provisions" in several warrants (Intracoastal Warrants 1, 2, 3, 4, and 5), which prevent exercise if it would result in ownership exceeding 9.99% or 4.99% for specific warrants.
• Without these blocker provisions, the Reporting Persons' potential beneficial ownership would be significantly higher, estimated at 2,874,124 shares as of May 21, 2025.
• The stake originated from a Securities Purchase Agreement (SPA) executed with Silo Pharma, Inc. on May 15, 2025, which involved the issuance of shares and warrants.

Sentiment

Score: 7

Explanation: The filing indicates a significant investment by an institutional group, which can be viewed positively as a vote of confidence in the company. While it's a regulatory disclosure, the underlying transaction (SPA with issuance of shares/warrants) suggests a capital infusion for Silo Pharma, Inc.

Positives

• A significant investment group, Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has taken a substantial 9.99% stake in Silo Pharma, Inc., potentially signaling confidence in the company's future.
• The acquisition of shares and warrants through a Securities Purchase Agreement indicates a direct investment into the company.

Risks

• The "blocker provisions" in the warrants limit the immediate exercise of a substantial number of shares, potentially restricting the Reporting Persons' ability to fully realize their potential ownership and influence if the share price were to rise significantly.
• The actual beneficial ownership is significantly lower than the potential ownership without blocker provisions (784,630 shares vs. 2,874,124 shares), which could be a point of confusion or misinterpretation for investors.

Future Outlook

NA

Industry Context

This filing reflects a significant investment by an institutional investor group in a publicly traded company, a common occurrence in the financial markets where investors acquire stakes for various strategic or investment purposes. The use of blocker provisions in warrants is a standard mechanism to manage beneficial ownership thresholds and avoid triggering certain regulatory or corporate governance requirements.

Stakeholder Impact

• Shareholders: The entry of a significant institutional investor group could be perceived positively, potentially increasing investor confidence and liquidity. The capital raise implied by the SPA could dilute existing shareholders, but also provides funding for the company's operations.
• Company Management: The investment provides capital and potentially validates the company's strategy, though the investors have certified they are not seeking to influence control.

Key Dates

Keywords

Silo Pharma Inc., Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Securities Purchase Agreement, Investment, Shareholder, SEC Filing